ER status

What it is

ER status is a breast cancer biomarker test that reports whether at least 1% of tumour cells stain for estrogen receptor. In practice, this result helps classify a breast cancer as ER-positive or ER-negative and is one of the most important factors used to decide whether endocrine therapy, such as tamoxifen or an aromatase inhibitor, is likely to help.

Estrogen receptors are proteins in or on cells that can bind the hormone estrogen. In many breast cancers, estrogen signaling supports tumour cell growth and survival. Because of that, pathology labs routinely test breast tumour tissue for estrogen receptor, usually along with progesterone receptor, or PR, and HER2. Mayo Clinic notes that ER-positive breast cancer is the most common type of breast cancer, and ER, PR, and HER2 results are central to treatment planning.

ER status is usually measured by immunohistochemistry, often abbreviated IHC, on tissue from a core biopsy or surgery specimen. The pathologist looks at how many invasive cancer cells stain for ER and how strong the staining is. A commonly used interpretation framework is shown below.

ER result	Typical meaning	Why it matters
ER-positive	At least 1% of tumour cell nuclei stain for ER	Endocrine therapy may reduce recurrence risk or help control advanced disease
ER-low positive	1% to 10% of tumour cells stain	Treated as ER-positive, but benefit from endocrine therapy may be smaller or less predictable
ER-negative	Less than 1% of tumour cells stain	Endocrine therapy is usually not effective

How it works

ER testing does not measure estrogen in the blood. It measures whether the cancer cells themselves express the estrogen receptor. Most clinical testing focuses on ER-alpha, the receptor subtype most relevant in breast cancer care.

If a tumour is ER-positive, estrogen can activate gene programmes that promote cell division and tumour persistence. That biology is why treatments that block the receptor or reduce estrogen levels can work. Examples include tamoxifen, which blocks ER signaling in breast tissue, and aromatase inhibitors, which lower estrogen production after menopause. In premenopausal patients, ovarian suppression may also be used.

The test is done on tumour tissue fixed in formalin and embedded in paraffin. The quality of the result depends on proper tissue handling, validated antibodies, and experienced pathology review. Poor fixation or technical variation can affect staining intensity and, in some cases, the final interpretation.

Evidence and uses

ER status is used mainly in breast cancer, where it has both prognostic and predictive value. Predictive means it helps estimate whether a treatment is likely to work. In ER-positive disease, endocrine therapy is often a standard part of treatment because it can lower the risk of recurrence in early-stage cancer and slow progression in metastatic cancer.

ER status is not interpreted alone. Doctors usually consider it together with:

1. PR status
2. HER2 status
3. Tumour grade
4. Stage and lymph node involvement
5. Menopausal status
6. Genomic assay results in selected early breast cancers

An ER-positive result does not mean every patient will respond equally well to hormone therapy. Tumours with strong, diffuse ER expression often behave differently from tumours with only 1% to 10% staining. This ER-low group is an area of active study. Current practice generally still considers these cancers ER-positive, but published reviews note that their biology and treatment response may overlap partly with ER-negative disease.

In India, ER testing is part of standard breast cancer pathology work-up in oncology centres and larger pathology laboratories. Access and quality can vary by setting, so patients may sometimes ask whether testing followed current pathology standards and whether PR and HER2 were also checked on the same specimen.

Diagnosis / how it's measured

ER status is usually reported on the pathology report after biopsy or surgery. The report may include the percentage of positive tumour cells, staining intensity, and sometimes a scoring system such as the Allred score or H-score, depending on the laboratory.

Common points on a pathology report include:

• Percentage positive cells: the proportion of invasive tumour cells with nuclear staining.
• Intensity: weak, moderate, or strong staining.
• Interpretation: ER-positive or ER-negative.
• ER-low positive: often used when staining is 1% to 10%.

Important practical details:

• Testing is usually done on invasive cancer, not just non-invasive components.
• A core needle biopsy is often enough for ER testing before treatment starts.
• If cancer returns or spreads, repeat biopsy may be advised because receptor status can change between the original tumour and recurrence.

No test is perfect. False-negative or borderline results can happen because of tissue handling problems, tumour heterogeneity, or technical issues in the lab. If the result seems inconsistent with the clinical picture, oncologists may discuss pathology review or repeat testing.

When to see a clinician

See your treating oncologist or breast surgeon if you have a new pathology report and do not understand the ER result. It is reasonable to ask for a copy of the full report and for an explanation of the exact percentage, whether the tumour is ER-low positive, and how PR and HER2 results fit with it.

You should also ask your clinician if:

• the report says ER low positive or equivocal
• the biopsy result and surgery result do not match
• the cancer has recurred or metastasised and no repeat receptor testing has been done
• treatment decisions are being made without a complete ER, PR, and HER2 profile

For patients in India, a second pathology review at a cancer centre may be useful if results are unclear or treatment would change based on a borderline finding.

Limitations and open questions

ER status is highly useful, but it is not the whole story. It does not by itself predict the exact chance of cure, recurrence, or drug response. Some clearly ER-positive cancers become resistant to endocrine therapy over time, while some ER-low cancers may derive limited benefit.

Evidence is still evolving on the best management of ER-low positive breast cancer. Reviews suggest this group may be biologically distinct from strongly ER-positive disease, but there is not complete agreement on how much endocrine therapy helps in every case. Research is also ongoing on ESR1 mutations, receptor cross-talk with HER2 and growth pathways, and mechanisms of endocrine resistance.

Another limitation is laboratory variability. Pre-analytic factors such as fixation time, analytic factors such as antibody selection, and interpretation differences between pathologists can affect results. That is why ER testing is most reliable when performed in accredited laboratories using standardised methods.

For patients and families, the key point is simple: ER status is a tissue-based biomarker that helps guide breast cancer treatment, especially the use of hormone-blocking therapy, but it must be interpreted with the rest of the pathology and the overall clinical picture.